Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JFL Life SciencesNSE:JFLLIFE 79 3-1 Month Momentum % is 39.68% as of Sep. 12, 2026. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 79/100 and a GF Value™ of ₹42.83 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,023 Drug Manufacturers companies, JFL Life Sciences ranks better than 93.45% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-12), JFL Life Sciences's 3-1 Month Momentum % is 39.68%.
The industry rank for JFL Life Sciences's 3-1 Month Momentum % or its related term are showing as below:
NSE:JFLLIFE's 3-1 Month Momentum % is ranked better than 93.45% of 1023
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs NSE:JFLLIFE: 39.68
JFL Life Sciences (NSE:JFLLIFE) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
JFL Life Sciences 3-1 Month Momentum % Related Terms
NSE:JFLLIFE vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's 3-1 Month Momentum % falls into.
JFL Life Sciences (NSE:JFLLIFE) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a 3-1 Month Momentum % of 39.68% as of Sep. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on JFL Life Sciences and its competitors. According to the industry distribution chart, JFL Life Sciences ranks #67 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 6.5%.
Is JFL Life Sciences' 3-1 Month Momentum % too high?
JFL Life Sciences' current 3-1 Month Momentum % is 39.68%. The Drug Manufacturers industry median 3-1 Month Momentum % is 3.13. JFL Life Sciences' value of 39.68% is 1167.7% above this industry median. Based on the distribution chart, JFL Life Sciences ranks #67 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JFL Life Sciences has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #67 out of 1023 companies for 3-1 Month Momentum %. This places JFL Life Sciences in the top 7% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 3.13. JFL Life Sciences' value of 39.68% is 1167.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 3.13, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current 3-1 Month Momentum % of 39.68% is 1167.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current 3-1 Month Momentum % is 39.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Possible Value Trap. The stock's GF Value™ is ₹42.83, compared to a current price of ₹10.65 — trading 75.1% below its estimated fair value. The current 3-1 Month Momentum % is 39.68% and 1167.7% above the Drug Manufacturers industry median of 3.13. JFL Life Sciences' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current 3-1 Month Momentum % is 39.68% as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.65 is trading 75.1% below its estimated GF Value™ of ₹42.83.
GuruFocus considers JFL Life Sciences to be Possible Value Trap.
Key valuation signals for NSE:JFLLIFE:
3-1 Month Momentum %: 39.68%
GF Value™: ₹42.83 vs. price of ₹10.65 (75.1% below fair value)
Industry Position: 1167.7% above the Drug Manufacturers median (#67 of 1023)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
79GF Score
Get the complete analysis for NSE:JFLLIFE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 
